Calciphylaxis requires close clinical monitoring of cutaneous lesions. When a structured first-line regimen has been applied and lesions remain active without adequate healing, escalation to adjunctive and experimental interventions becomes the clinical question.
The initial multipronged approach — centred on intravenous sodium thiosulfate, withdrawal of risk-inducing medications, wound care with debridement, and multimodal analgesia — targets healing of cutaneous calciphylaxis lesions. When close monitoring shows that active lesions are not healing on this regimen, escalation is indicated.
After first-line failure, further options from adjunctive and experimental categories may be considered — including agents belonging to a class of pyrophosphate analogues, along with select procedural and renal interventions. The specific agents, their sequencing, and the full decision algorithm are contained in the complete protocol.
Slowed progression of calciphylaxis skin lesions within weeks of initiating escalation therapy; healing of cutaneous lesions over subsequent months with appropriate interventions.
DOI: 10.1053/j.ajkd.2022.06.011
Bisphosphonates, which are pyrophosphate analogues, may offer therapeutic benefit for patients with calciphylaxis in the setting of ESKD.
A prospective series of 11 such patients found that the addition of bisphosphonates slowed calciphylaxis progression in all patients 2-4 weeks after starting treatment and significantly improved outcomes compared with patients managed with supportive therapies only (debridement, low-calcium dialysate).
In a retrospective study of 34 patients with calciphylaxis, half of the patients who underwent hyperbaric oxygen therapy had complete healing after 44 sessions of therapy over 2 months.
View source ↗